Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023)
Mira Pharmaceuticals (MIRA) posted Total Non-Current Liabilities of $558097.0 for Q4 2023, down 58.79% sequentially from $1.4 million in Q4 2022, and down 58.79% YoY from $1.4 million in Q4 2022.
Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals has reported Total Non-Current Liabilities for 2 years, with the latest figure at $558097.0 in Q4 2023.
- Quarterly Total Non-Current Liabilities fell 58.79% year-over-year to $558097.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $558097.0 (down 58.79% YoY) and the FY2023 annual result came in at $558097.0, down 58.79% from the prior year.
- Total Non-Current Liabilities eased to $558097.0 in Q4 2023 per MIRA's latest filing, from $1.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.4 million in Q4 2022 and troughed at $558097.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Mira Pharmaceuticals | 18.47 Mn | 7.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 558,097.00 |
| Dec 31, 2022 | 1.35 Mn |